Syntax Research Inc. Decreases Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Syntax Research Inc. decreased its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 29.0% in the third quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 245 shares of the biopharmaceutical company’s stock after selling 100 shares during the quarter. Syntax Research Inc.’s holdings in Regeneron Pharmaceuticals were worth $258,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Sachetta LLC grew its holdings in Regeneron Pharmaceuticals by 71.4% during the 2nd quarter. Sachetta LLC now owns 24 shares of the biopharmaceutical company’s stock valued at $26,000 after purchasing an additional 10 shares during the last quarter. Rakuten Securities Inc. grew its stake in shares of Regeneron Pharmaceuticals by 380.0% during the third quarter. Rakuten Securities Inc. now owns 24 shares of the biopharmaceutical company’s stock valued at $25,000 after buying an additional 19 shares during the last quarter. Stephens Consulting LLC purchased a new stake in shares of Regeneron Pharmaceuticals in the second quarter worth approximately $26,000. FSA Wealth Management LLC purchased a new stake in shares of Regeneron Pharmaceuticals in the third quarter worth approximately $26,000. Finally, Family Firm Inc. bought a new stake in shares of Regeneron Pharmaceuticals during the 2nd quarter worth approximately $33,000. Hedge funds and other institutional investors own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Stock Performance

Shares of REGN stock opened at $740.01 on Wednesday. Regeneron Pharmaceuticals, Inc. has a 52-week low of $721.08 and a 52-week high of $1,211.20. The company has a quick ratio of 4.46, a current ratio of 5.28 and a debt-to-equity ratio of 0.09. The stock has a market cap of $81.32 billion, a PE ratio of 18.31, a price-to-earnings-growth ratio of 2.19 and a beta of 0.08. The business has a 50-day simple moving average of $839.04 and a 200-day simple moving average of $1,000.86.

Wall Street Analyst Weigh In

Several equities analysts have commented on the company. StockNews.com downgraded Regeneron Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Monday, November 4th. Wells Fargo & Company reduced their price target on shares of Regeneron Pharmaceuticals from $1,200.00 to $1,050.00 and set an “overweight” rating on the stock in a research note on Tuesday, October 22nd. Cantor Fitzgerald reiterated a “neutral” rating and set a $1,015.00 price objective on shares of Regeneron Pharmaceuticals in a report on Wednesday, October 23rd. Canaccord Genuity Group assumed coverage on shares of Regeneron Pharmaceuticals in a research note on Tuesday. They issued a “hold” rating and a $165.00 target price on the stock. Finally, Citigroup assumed coverage on shares of Regeneron Pharmaceuticals in a research note on Thursday, November 14th. They set a “neutral” rating and a $895.00 price target for the company. One equities research analyst has rated the stock with a sell rating, six have given a hold rating, sixteen have given a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, Regeneron Pharmaceuticals presently has an average rating of “Moderate Buy” and an average target price of $1,052.90.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.